BRISTOL-MYERS SQUIBB CO

BMY is the ticker symbol for Bristol-Myers Squibb Company, a global biopharmaceutical company traded on the New York Stock Exchange. The company focuses on discovering, developing, and delivering innovative medicines for serious diseases, including cancer, cardiovascular conditions, and immunological disorders. BMY stock represents an ownership stake in this healthcare enterprise.

Recent performance for BMY can vary based on market conditions, company news, and sector trends. To see the latest price changes and performance metrics, please refer to the current data displayed on this page. This will provide the most up-to-date information on how BMY has been trading.

Evaluating BMY's valuation involves comparing metrics like the price-to-earnings (P/E) ratio, price-to-sales, and enterprise value to EBITDA against peers in the pharmaceutical industry. Investors also consider growth prospects, pipeline strength, and dividend yield. For current valuation multiples, please check the financial data provided on this page.

Yes, Bristol-Myers Squibb pays a quarterly dividend to shareholders. The company has a history of returning capital through dividends, though the amount can change over time. For the current dividend rate and yield, please refer to the latest data on this page. Dividend payments are subject to board approval.

Key risks for BMY include clinical trial failures, regulatory setbacks, patent expirations, and competition from generic drugs. The pharmaceutical sector also faces pricing pressures and litigation risks. Additionally, economic downturns and changes in healthcare policy can impact performance. Investors should review BMY's risk factors in its SEC filings for a comprehensive understanding.

Important metrics for BMY include revenue growth, net income, earnings per share (EPS), and operating cash flow. Investors also monitor research and development spending, gross margins, and debt levels. These indicators help assess the company's profitability and financial health. For specific figures, consult BMY's quarterly and annual reports.